Working groups
Dr Felicia Schlotthauer is a molecular biologist with a background in virology and immunology research. Felicia moved to Melbourne to pursue a PhD in the Viral Entry and Vaccines Group at Burnet Institute under Professor Heidi Drummer.
After successful completion of her PhD in 2022, Felicia gained experience in quality management while working as a Quality Assurance Officer for the Burnet Diagnostic Initiative (BDI).
Following her excursion into the world of quality management, Felicia took on a role as Research Officer in the BDI, with the main focus of identification and feasibility studies of new diagnostics to feed the development pipeline. In the last four months of the role, she was the inaugural acting team leader of the scientific team.
As the Project Manager in the BDI, her responsibilities include managing all product development projects to assist the impact of the BDI, through the commercialisation of intellectual property and research outcomes. This includes identifying research to be licensed, providing expert advice on commercialisation, building networks to identify opportunities for research commercialisation, and managing stakeholders.
More recently, Felicia has been appointed the Commercial Project Manager for the Office for Research Translation (ORT). The ORT brings together research translation initiatives including Burnext, the Burnet Diagnostics Initiative (BDI) and the Burnet Vaccine Initiative (BVI).
Prior to moving to Melbourne and joining Burnet, Felicia completed both her bachelor’s and master’s degrees at the University of Luebeck in Germany. During this time, she also gained industry experience during an internship at the pharmaceutical company Boehringer Ingelheim.
Youth & Society
Caitlin Douglass, Merryn Roe, Michelle Raggatt, Felicia Schlotthauer, Stephanie Main, Megan S. C. Lim, Lindi Masson
PLoS Pathogens
Felicia Schlotthauer
Viruses
Felicia Schlotthauer, Joey McGregor, Heidi E. Drummer, Felicia Schlotthauer, Joey McGregor, Heidi E. Drummer
We’re developing a novel class of antibody and delivery technologies to provide enhanced protection and therapeutic performance for coronaviruses and other respiratory infections.
A rapid point-of-care (POC) test for liver disease biomarkers could improve the management of acute and chronic liver disease and reduce the progression to liver cancer in Australia and globally.
We're developing point-of-care diagnostics for active syphilis, aiming to transform syphilis management globally and contribute to World Health Organization goals.